Biologic injections Queen Creek: what are these blood-based choices?

Why does my joint still ache?

A joint doesn't need a fresh injury to become sore. Long use can make the smooth joint surfaces rougher.

Your knee may complain on stairs or after a long walk. A shoulder often aches with an overhead reach or while you sleep.

Hip soreness can start when you rise from a chair. It may ease after a few steps, then return later.

Notice the time the soreness starts and the motion that sets it off. That's useful when the doctor focuses the exam.

A mild flare sometimes eases after a quieter day. Gentle motion often feels better than pushing through sharp soreness.

Are biologic injections and orthobiologics blood-based shots?

Yes. Biologic injections use blood or marrow taken from your body for the shot.

At clinics, orthobiologics is the group name for those treatments. The word doesn't mean one single type of care.

Platelet-rich plasma, known as PRP, begins with a small arm blood draw. Staff spin that blood in a machine before using it.

The spinning gathers platelets, tiny blood parts that help with clotting. Those parts sit in the liquid used for the sore joint.

At QC Kinetix, regenerative treatments refers to the same blood and marrow choices. Its medical providers, the trained staff who examine and care for you, handle the visit.

The purpose is less soreness and easier movement, but results aren't certain. These treatments haven't been shown to rebuild worn joint surfaces.

What can I try before surgery?

A quieter day, gentle motion, and a cool pack may ease a flare. Don't force a movement that brings sharp soreness.

If daily chores stay hard, an exam may save you guesswork. QC Kinetix can discuss non-surgical care after checking the joint.

Its natural pain treatments are the blood- or marrow-based choices described above. Joint preservation means trying to keep you moving and delay surgery.

You won't have to choose during the first talk. Ask what is being suggested, what it may cost, and what happens next.

Sources

1. FDA states verbatim of stem cell products, stromal vascular fraction (adipose-derived cells), umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products: 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders of blood production, and there are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.

2. The 2015 Annals network meta-analysis of 137 studies (33,243 participants) compared oral and injected drugs for knee OA and found ALL interventions significantly outperformed oral placebo for pain, with intra-articular hyaluronic acid the most efficacious (effect size 0.63) and acetaminophen the least (0.18). Intra-articular treatments outperformed NSAIDs, which the authors noted may partly reflect the integrated effect of the injection process itself.

   Bannuru RR, et al. — Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis.. Annals of Internal Medicine, 2015. DOI: 10.7326/M14-1231.

3. The BMJ meta-analysis of viscosupplementation pooled 169 trials (21,163 participants) and found clear evidence of small-study effects and publication bias. In the prespecified main analysis of 24 LARGE placebo-controlled trials (8,997 participants) hyaluronic acid reduced pain by SMD -0.08 (95% CI -0.15 to -0.02), equivalent to 2.0 mm on a 100 mm scale - far below the -0.37 minimal important difference - and trial sequential analysis showed there has been CONCLUSIVE evidence of clinical equivalence to placebo since 2009. Fifteen large trials showed a significantly higher risk of serious adverse events (RR 1.49).

   Pereira TV, et al. — Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis.. BMJ, 2022. DOI: 10.1136/bmj-2022-069722.

4. A Bayesian network meta-analysis of 48 Level I-II randomized trials (9,338 knees) with a minimum 6-month follow-up ranked the four commonest intra-articular injections. HA and PRP both significantly improved pain versus placebo; HA, PRP and BMAC all significantly improved function versus placebo. SUCRA rankings were PRP 91.54, BMAC 76.46, HA 53.12, corticosteroid 15.18 and placebo 13.70 - corticosteroid ranked barely above placebo at six months and beyond.

   Jawanda H, et al. — Platelet-Rich Plasma, Bone Marrow Aspirate Concentrate, and Hyaluronic Acid Injections Outperform Corticosteroids in Pain and Function Scores at a Minimum of 6 Months as Intra-Articular Injections for Knee Osteoarthritis: A Systematic Review and Network Meta-analysis.. Arthroscopy, 2024. DOI: 10.1016/j.arthro.2024.01.037.

5. A network meta-analysis of 43 trials (5,554 patients) reached the OPPOSITE ranking to the more recent orthobiologic-favourable reviews: steroids ranked most likely to be effective for pain and function, with adipose MSC and multiple PRP ranked LEAST likely; single PRP, multiple PRP and adipose MSC did not produce a relevant reduction in pain or improvement in function versus placebo. The authors noted treatment-effect differences were small and potentially not clinically meaningful either way.

   Han SB, et al. — Intra-Articular Injections of Hyaluronic Acid or Steroids Associated With Better Outcomes Than Platelet-Rich Plasma, Adipose Mesenchymal Stromal Cells, or Placebo in Knee Osteoarthritis: A Network Meta-analysis.. Arthroscopy, 2021. DOI: 10.1016/j.arthro.2020.03.041.

6. A network meta-analysis restricted to LARGE randomized trials (at least 100 patients per group; 57 RCTs, 22,795 participants, 18 intra-articular interventions) found treatment effects were consistently larger in the 35 high-risk-of-bias trials than in the 22 low/unclear-risk trials. In the main analysis excluding high-risk trials, triamcinolone had the highest probability of exceeding the minimal important difference at weeks 2 and 6; hyaluronic acid had no effect on pain (SMD -0.04, 95% CrI -0.19 to 0.11, 11 trials) but higher odds of dropouts due to adverse events (OR 2.01) and of serious adverse events (OR 1.86). The effects of 16 of the 18 interventions were smaller than the MID and most were consistent with placebo effects.

   Pereira TV, et al. — Effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis based on large randomized trials: A systematic review and network meta-analysis.. Osteoarthritis and Cartilage, 2025. DOI: 10.1016/j.joca.2024.08.014.